Analysis Of Income And Expense [Abstract]

ChemoMetec - Filing #1269875

Concept 2023-07-01 to
2024-06-30
2023-07-01 to
2024-06-30
2023-07-01 to
2024-06-30
2023-07-01 to
2024-06-30
2023-07-01 to
2024-06-30
2022-07-01 to
2023-06-30
2022-07-01 to
2023-06-30
2022-07-01 to
2023-06-30
2022-07-01 to
2023-06-30
2022-07-01 to
2023-06-30
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
407,350 DKK
442,274 DKK
Expenses by nature [abstract]
Raw materials and consumables used
68,098 DKK
60,359 DKK
Classes of employee benefits expense [abstract]
Employee benefits expense
135,226 DKK
115,754 DKK
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense
17,209 DKK
20,469 DKK
Other expenses, by nature
46,194 DKK
44,716 DKK
Disclosure of attribution of expenses by nature to their function [text block]
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
69,600 DKK
- DKK
136,689 DKK
4,000 DKK
67,085 DKK
104,415 DKK
71,497 DKK
175,904 DKK
- DKK
8,000 DKK

Talk to a Data Expert

Have a question? We'll get back to you promptly.